Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Century Therapeutics, Inc. - Common Stock (NQ:IPSC)

0.6230 -0.0367 (-5.56%)
Streaming Delayed Price Updated: 11:14 AM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Century Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Monday's after hours session: top gainers and losers
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
4 Analysts Have This To Say About Century Therapeutics
 
Via Benzinga
5 Analysts Assess Century Therapeutics: What You Need To Know
 
Via Benzinga
Demystifying Century Therapeutics: Insights From 4 Analyst Reviews
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Century Therapeutics Stages Highest Single Day Move In 11 Months As Casdin Capital Bumps Its Stake To 5.4%
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Robinhood To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
Century Therapeutics: Q4 Earnings Insights
 
Via Benzinga
Recap: Century Therapeutics Q3 Earnings
 
Via Benzinga
Century Therapeutics: Q1 Earnings Insights
 
Via Benzinga
IPSC Stock Earnings: Century Therapeutics Beats EPS for Q2 2024
IPSC stock results show that Century Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
IPSC Stock Earnings: Century Therapeutics Beats EPS, Misses Revenue for Q1 2024
IPSC stock results show that Century Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing
Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D... 
Via Benzinga
IPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023
IPSC stock results show that Century Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
3 Millionaire-Maker Under-$10 Stocks to Buy in February 2024
While not on everyone’s radar, these enticing entities just might deliver the goods. 
Via InvestorPlace
IN8bio's Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data
IN8bio (NASDAQ: INAB) is a biotechnology company that specializes in developing novel therapies based on gamma-delta T cells. Its innovative technology focuses on harnessing the potential of these... 
Via Benzinga
Analyst Ratings for Century Therapeutics
 
Via Benzinga
Century Therapeutics's Return On Capital Employed Overview
 
Via Benzinga
Where Century Therapeutics Stands With Analysts
 
Via Benzinga
Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December
Amidst fanfare for Nasdaq 100, U.S. small-cap stocks rally, with Russell 2000 index reaching levels not seen since Aug. 2022, 80% of stocks trading above 50-day MA, outperforming large caps &... 
Via Benzinga
Topics ETFs
Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential
Although speculative ideas tend to be losers more so than winners, these 10-bagger penny stocks might tempt the gambler. 
Via InvestorPlace
Harnessing The Power Of Gamma-Delta T Cells In Cancer Therapy: IN8bio's Innovative Approach
Why Are Gamma-Delta T Cells Important In Fighting Cancer? 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
 
Via Benzinga
Workday To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Monday
Truist Securities raised the price target for Church & Dwight Co., Inc. (NYSE: CHD) from $95 to $105. Truist Securities analyst Bill Chappell upgraded the stock from Hold to Buy. Church & Dwight shares... 
Via Benzinga
These Analysts Slash Their Forecasts On Century Therapeutics After Weak Q2 Results
Century Therapeutics, Inc. (NASDAQ: IPSC) reported weaker-than-expected second-quarter results. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 29 stocks made new 52-week lows. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.